 | | Vol. 14.46 – 28 November, 2023 |
| |
|
|
| Researchers conducting a Phase I/II, open-label, multicenter trial aimed at optimizing cell engraftment with device-encapsulated pancreatic precursor cells, and reported interim, one-year outcomes.
[Nature Biotechnology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators demonstrated that early postnatal growth of the pancreas unexpectedly involved massive acinar cell elimination.
[Cell Reports] |
|
|
|
| Type 2 diabetes mice were fed with a goat-milk-based diet containing 10.3% w/w goat milk powder for ten weeks for investigating the in vivo effects; a β cell line MIN6 cells were used to test the in vitro effects of digested goat milk.
[Molecular Nutrition & Food Research] |
|
|
|
| | Scientists observed that by reducing the membrane localization of MRAS, hypomethylation conditions produced an imbalance in KRAS signaling, resulting in the partial inactivation of ERK and hyperactivation of the PI3K/AKT–mTORC1 pathway.
[Cell Death & Disease] |
|
|
|
| The authors found that high TACC3 expression in PDAC was associated with poor prognosis. shRNA-mediated TACC3 knockdown caused S phase arrest of the cell cycle and inhibited proliferation in PDAC cell lines.
[Cell Death & Disease] |
|
|
|
| Unbiased transcriptome and metabolome analyses showed that PDAC cells with disrupted KRASG12D-NRF2 signaling (NRF2−/− cells) shifted from aerobic glycolysis to metabolic pathways fed by amino acids.
[iScience] |
|
|
|
| Researchers examined the CCCTC-binding factor (CTCF) function in pancreatic cancer (PC) and discovered that CTCF expression in PC tissues was significantly raised compared to neighboring healthy tissues.
[Heliyon] |
|
|
|
| By exploring microbial cultures as a source, researchers found new compounds, namely, adenopeptins B and C, from Acremonium sp. ESF00140. 1 and 2 selectively and potently inhibited the sphere formation of pancreatic cancer cells cultured in the fibroblast conditioned medium compared with the control medium.
[Journal Of Antibiotics] |
|
|
|
|
| Investigators cover all the major nanotechnology-based patent litrature available on renowned patent data bases like Patentscope and Espacenet, through the time period of 2007-2022.
[Expert Opinion On Therapeutic Patents] |
|
|
|
|
| The approval of approval of Tzield (teplizumab) in November of 2022, the first-ever disease-modifying drug for Type 1 diabetes, boosted screening momentum for diabetes.
[University of Colorado] |
|
|
|
|
| January 16 – 19, 2024
San Diego, California, United States & Virtual |
|
|
|
|
|
| | BC Cancer – Vancouver, British Columbia, Canada |
|
|
|
| | Babraham Institute – Cambridge, England, United Kingdom |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | Armenian Bioinformatics Institute – Yerevan, Armenia |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
